Consistent Efficacy of Eptinezumab as Migraine Prevention Treatment: Jessica Ailani, MD

WATCH TIME: 5 minutes

"If you did well, greater than 50% response in that first treatment dose, the chances of you doing well for the full 18 months were very high."

The multi-site, randomized, parallel-group, double-blinded, placebo-controlled DELIVER trial (NCT04418765), assessing eptinezumab (Vyepti; Lundbeck), enrolled patients with migraine who had failed between 2 and 4 previous preventive migraine therapies. Previous findings from DELIVER showed that patients treated with eptinezumab reported significant reductions in mean monthly migraine days (MMDs) and had achieved at least a 50% migraine response compared with placebo over 18 months.

In a recent analysis of the trial, clinical response to eptinezumab preventive treatment was maintained in most patients if they reported an at least a 50% migraine response following the initial 1–2 doses.¹ For at least 50% migraine responders in the first dose, 61% and 74% maintained an at least 50% response to eptinezumab 100 mg (n = 113) and eptinezumab 300 mg (n = 126), respectively, for 18 months. For those who achieved at least a 50% migraine response to the first 2 doses of eptinezumab, 69% of those on eptinezumab 100 mg (n = 128) and 82% of those on 300 mg (n = 131) maintained a 50% responder status over the remaining 4 doses .

These findings were presented at the 2024 American Academy of Neurology (AAN) Annual Meeting, held April 13-18, in Denver, Colorado, by Jessica Ailani, MD, director of the MedStar Georgetown Headache Center. At the meeting, Ailani sat down with NeurologyLive^® to further discuss how the 2 doses of medication were used in the study. She also explained the main objective of analyzing patient response in this analysis. In addition, Ailani talked about how the data may impact the clinical practice when treating patients with migraine.

Click here for more coverage of AAN 2024.

REFERENCES
1. Ailani J, Soni-Brahmbhatt S, Awad S, et al. Long-term Maintenance of ≥50% Migraine Response with Eptinezumab Treatment in Patients with 2–4 Prior Preventive Migraine Treatment Failures. Presented at: 2024 AAN Annual Meeting; April 13-18; Denver, CO.